{"analyses":[{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.02","estimateComment":"Stratified by Region and RPA Class.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0987","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalComment":"Stratified by Region and RPA Class","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.5","upperLimit":"18.5","value":"16.8"},{"groupId":"OG001","lowerLimit":"15.4","upperLimit":"18.4","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"458"},{"groupId":"OG001","value":"463"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"In the Concurrent Phase participants received radiotherapy (RT) in daily fractions of 2 Gray (Gy) given 5 days per weeks for 6 weeks (for a total of 60 Gy) and temozolomide 75 milligrams per square meter (mg/m\\^2) daily from the first day to the last day of radiotherapy (for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab (Avastin) 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m\\^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity. Participants then entered the last period: After Primary Overall Survival Analysis, in which participants were followed up for safety.","id":"OG000","title":"Bevacizumab + RT + Temozolomide"},{"description":"In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 weeks (for a total of 60 Gy) and temozolomide 75 mg/m\\^2 daily from the first day to the last day of radiotherapy (for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m\\^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity. Participants then entered the last period: After Primary Overall Survival Analysis, in which participants were followed up for safety.","id":"OG001","title":"Placebo + RT + Temozolomide"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population.","reportingStatus":"POSTED","timeFrame":"Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months])","title":"Co-Primary: Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}